Pharmacy Benefit Manager (PBM) Reform
The Bottom Line
S. 882 and S. 3345 are bills that would change how pharmacy benefit managers (PBMs) make money by requiring flat fees and banning 'spread pricing.' These bills matter because they would force PBMs to pass 100% of drug rebates to Medicare patients and allow more local pharmacies to join insurance networks. Both measures are currently in committee as part of a bipartisan effort to lower prescription drug costs.
Key Statements
“GOPoversight exposed how the three largest PBMs colluded to line their own pockets. These self-benefitting tactics have done nothing but jeopardize patient care.”
This post highlights the specific allegations of collusion and patient harm that drive the push for PBM reform.
“Pharmacy benefit managers shouldn’t steer patients to affiliated pharmacies and treatments regardless of price or effectiveness.”
This quote directly addresses the 'steering' practice that S. 882 and S. 3345 aim to restrict.
Policies— 2 policys
S. 882 and S. 3345 are complementary Senate bills; S. 882 focuses on Medicare rebate pass-throughs and flat fees, while S. 3345 targets Medicaid transparency and spread pricing. They are often discussed together as a package alongside House companion bills like HR 7148 to provide a comprehensive overhaul of PBM business practices.
Who This Affects
10 groupsConflicting
Helps
Political Response
0 statementsAnalysis generated by AI. Always verify with official sources.